One Plus One Equals Three For Calluna

Two early-stage companies have merged to form Calluna Therapeutics, which is targeting immunological diseases and hopes to get to proof of concept by mid-2026.

Merging two companies and securing a €75m ($81m) series A venture round is not an unimpressive achievement, particularly when the combined group is yet to achieve proof of concept, and is active in the tricky and competitive arena of immunology. But Calluna Pharma emerged last week in just this manner, and has given itself three years to prove its pipeline’s value.

Key Takaways

Oxitope Pharma and Arxx Therapeutics have merged to form Calluna Pharma

Calluna does have a bit of a leg-up in that its CEO John Montana, is, in addition to his duties...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins

05 Jun 2025

• By Mandy Jackson

Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

05 Jun 2025

• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.